Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ondine Biomedical (FRA:VF5) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Ondine Biomedical Net Margin % Related Terms
Ondine Biomedical Net Margin % Historical Data
* Premium members only.
The historical data trend for Ondine Biomedical's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VF5 vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, Ondine Biomedical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Net Margin % distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ondine Biomedical (FRA:VF5) has a Net Margin % of -1,038.38% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Ondine Biomedical and its competitors. According to the industry distribution chart, Ondine Biomedical ranks #754 out of 945 companies in the Biotechnology industry, placing it in the top 79.8%.
Is Ondine Biomedical's Net Margin % too high?
Ondine Biomedical's current Net Margin % is -1,038.38%. Based on the distribution chart, Ondine Biomedical ranks #754 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ondine Biomedical has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #754 out of 945 companies for Net Margin %. This places Ondine Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current Net Margin % is -1,038.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.13 — trading 45.6% above its estimated fair value. The current Net Margin % is -1,038.38%. Ondine Biomedical's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current Net Margin % is -1,038.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of €0.13 is trading 45.6% above its estimated GF Value™ of €0.09.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for FRA:VF5:
Net Margin %: -1,038.38%
GF Value™: €0.09 vs. price of €0.13 (45.6% above fair value)
No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
41GF Score
Get the complete analysis for FRA:VF5
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VF5 has been successfully added to your 
